Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.

Authors:
Aderonke Odutola
Aderonke Odutola
London School of Hygiene and Tropical Medicine
United Kingdom
Martin Antonio
Martin Antonio
Medical Research Council Unit
United States
Ezra O Ogundare
Ezra O Ogundare
Obafemi Awolowo University Teaching Hospital and Obafemi Awolowo University
Nigeria
Patrick K Owiafe
Patrick K Owiafe
Medical Research Council Unit
United Kingdom
Archibald Worwui
Archibald Worwui
Medical Research Council Unit
Olubukola T Idoko
Olubukola T Idoko
Clinical Sciences Building
United Kingdom

Vaccine 2019 May 8;37(19):2586-2599. Epub 2019 Apr 8.

GSK, Wavre, Belgium. Electronic address:

Background: Two conserved pneumococcal proteins, pneumolysin toxoid (dPly) and pneumococcal histidine triad protein D (PhtD), combined with 10 polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) in two investigational pneumococcal vaccine (PHiD-CV/dPly/PhtD) formulations were immunogenic and well-tolerated when administered to Gambian children. Here, we report immunogenicity of the polysaccharide conjugates, and immunogenicity and reactogenicity of co-administered routine vaccines.

Methods: In this phase II, controlled, observer-blind, single-centre study, healthy infants aged 8-10 weeks were randomised (1:1:1:1:1:1) to six groups. Four groups received 3+0 schedule (2-3-4 months [M]) of PHiD-CV/dPly/PhtD (10 or 30 µg of each protein), PHiD-CV, or 13-valent pneumococcal conjugate vaccine; and two groups received 2+1 schedule (2-4-9 M) of PHiD-CV/dPly/PhtD (30 µg of each protein) or PHiD-CV. All infants received diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b (DTPw-HBV/Hib) and oral trivalent polio vaccines (OPV) at 2-3-4 M, and measles, yellow fever, and OPV vaccines at 9 M. We evaluated immune responses at 2-5-9-12 M; and reactogenicity 0-3 days post-vaccination.

Results: 1200 infants were enrolled between June 2011 and May 2012; 1152 completed the study. 1 M post-primary vaccination, for each PHiD-CV serotype except 6B and 23F, ≥97.4% (3+0 schedule) and ≥96.4% (2+1 schedule) of infants had antibody concentrations ≥0.2 μg/mL. Immune responses were comparable between groups within the same vaccination schedules. Observed antibody geometric mean concentrations (GMCs) increased by 1 M post-primary vaccination compared to pre-vaccination. In the following months, GMCs and opsonophagocytic activity titres waned, with an increase post-booster for the 2+1 schedule. Immune responses to protein D and, DTPw-HBV/Hib, OPV, measles, and yellow fever vaccines were not altered by co-administration with pneumococcal proteins. Reactogenicity of co-administered vaccines was comparable between groups and did not raise concerns.

Conclusion: Immune responses to the 10 PHiD-CV polysaccharide conjugates and co-administered vaccines were not altered by addition of dPly and PhtD. ClinicalTrials.gov identifier NCT01262872.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0264410X193035
Publisher Site
http://dx.doi.org/10.1016/j.vaccine.2019.03.033DOI Listing
May 2019
16 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 15, 2019, 10:53 am EST

Publication Analysis

Top Keywords

immune responses
16
pneumococcal proteins
12
2+1 schedule
12
reactogenicity co-administered
12
polysaccharide conjugates
12
measles yellow
8
groups received
8
yellow fever
8
post-primary vaccination
8
co-administered routine
8
immunogenicity reactogenicity
8
vaccines altered
8
phid-cv/dply/phtd 30 µg
8
comparable groups
8
co-administered vaccines
8
pneumococcal conjugate
8
protein phid-cv
8
30 µg protein
8
conjugate vaccine
8
1 m post-primary
8

Similar Publications